ANI Pharmaceuticals, Inc. (ANIP) News
Follow ANI Pharmaceuticals, Inc. (ANIP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 31 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ANI Pharmaceuticals Reports Results for Quarter Ended September 30
EARNINGS | Nov 05, 2026, 03:19 PM UTC
M
ANI Pharmaceuticals Reports Q3 Results, Raises Adjusted EBITDA and EPS Guidance
Quarterly net revenue rose 27.6% year over year. ANI narrowed 2026 revenue guidance to $1,085–$1,125 million and raised adjusted non-GAAP EBITDA guidance to $290–$300 million. Adjusted diluted EPS was $2.70 for the quart
EQUITY | Nov 05, 2026, 02:03 PM UTC
M
ANI Pharmaceuticals raises 2026 adjusted EPS view to $9.37–$9.71
EARNINGS | Nov 05, 2026, 12:05 PM UTC
M
ANI Pharmaceuticals Reports Third-Quarter Revenue of $290.8 Million
EQUITY | Nov 05, 2026, 11:58 AM UTC
M
ANI Pharmaceuticals Q3 Net Income Rises 32% to $35.15 Million
EARNINGS | Nov 05, 2026, 11:55 AM UTC
M
ANI Pharmaceuticals Adjusts 2026 Revenue View to $1.09B–$1.13B
EARNINGS | Nov 05, 2026, 11:54 AM UTC
M
ANI Pharmaceuticals Q3 Revenue Reaches $290.777 Million
Q3 revenue was $290.777 million, compared with an IBES estimate of $280.2 million.
EQUITY | Nov 05, 2026, 11:54 AM UTC
M
ANI Pharmaceuticals Offers to Acquire Egetis Therapeutics
ANI Pharmaceuticals announced an offer to acquire Egetis Therapeutics, expanding its rare disease business.
EQUITY | Nov 05, 2026, 11:52 AM UTC
L
ANI Pharmaceuticals reports third-quarter adjusted EPS of $2.70
EARNINGS | Nov 05, 2026, 11:52 AM UTC
M
ANI Pharmaceuticals Reports Third-Quarter 2026 Results
EQUITY | Nov 05, 2026, 11:52 AM UTC
M
ANI Pharmaceuticals forecasts FY revenue of USD 1,085–1,125 million
The company’s FY revenue outlook compares with an IBES estimate of USD 1,102 million.
EARNINGS | Nov 05, 2026, 11:52 AM UTC
M
ANI Pharmaceuticals forecasts FY adjusted EBITDA of $290–300 million
EARNINGS | Nov 05, 2026, 11:51 AM UTC
L
ANI Pharmaceuticals Reports Q3 Net Income of $35.1 Million
EARNINGS | Nov 05, 2026, 11:51 AM UTC
M
ANI Pharmaceuticals Reports Q3 2026 Results
Quarterly net revenues were $290.8 million, up 27.6% year over year.
EQUITY | Nov 05, 2026, 11:51 AM UTC
M
ANI Pharmaceuticals Offers to Acquire Egetis Therapeutics for About $560 Million
ANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics AB.
EQUITY | Nov 05, 2026, 09:17 AM UTC
M
Egetis Board Recommends ANI Pharmaceuticals’ Cash Offer
Egetis Therapeutics’ board recommends ANI Pharmaceuticals’ cash offer.
MNA | Nov 05, 2026, 06:41 AM UTC
L
ANI Pharmaceuticals launches duloxetine delayed-release capsules
EQUITY | Oct 19, 2026, 10:55 AM UTC
H
ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026Post-hoc analyses of baseline characteristics and efficacy outcomes
NEWS | Sep 30, 2026, 10:58 AM UTC
L
Weekly Recap: Everolimus suspension FDA OK and Oppenheimer $85 target
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) won final FDA approval for its Everolimus oral suspension ANDA (2, 3, 5 mg), targeting a branded U.S. market of about $123 million annually, and Oppenheimer set an $85 per-share pr
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughl
REGULATION | Sep 23, 2026, 08:42 PM UTC
L
ANI Pharmaceuticals Price Target Announced at $85.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) ANI Pharmaceuticals Initiated at Perform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:14 PM UTC
L
ANI Pharmaceuticals, Inc. (ANIP) Wins FDA OK for Everolimus Oral Suspension Generic
ANI Pharmaceuticals received FDA final approval for its ANDA for Everolimus Tablets for Oral Suspension (2mg, 3mg, 5mg), the generic of Afinitor Disperz. U.S. annual sales for the reference market are approximately $123M
REGULATION | Sep 23, 2026, 11:02 AM UTC
L
ANIP - ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
ANIP - ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
REGULATION | Sep 23, 2026, 10:55 AM UTC
H
ANIP: Rare disease focus, sales force expansion, and clinical data drive strong growth outlook
The company is rapidly expanding its rare disease portfolio, with Cortrophin Gel and ILUVIEN driving growth and a strong generics business funding further investment. Revised 2026 guidance reflects Q1 headwinds, but robu
EARNINGS | Sep 15, 2026, 04:44 PM UTC
L
ANI Pharmaceuticals CEO to take part in September investor fireside chats
ANI Pharmaceuticals said CEO Nikhil Lalwani and members of its executive leadership team will participate in fireside chats at September investor conferences.
EQUITY | Sep 03, 2026, 10:57 AM UTC
L
ANIP - ANI Pharmaceuticals to Present at September Investor Conferences
ANIP - ANI Pharmaceuticals to Present at September Investor Conferences
EQUITY | Sep 03, 2026, 10:55 AM UTC
L
ANI Pharmaceuticals appoints Henry Gosebruch to board
ANI Pharmaceuticals says it has appointed Henry Gosebruch to its board of directors.
REGULATION | Aug 24, 2026, 10:55 AM UTC
L
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ: ANIP ) reported upbeat earnings for the second quarter on Friday. The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. Th
EARNINGS | Aug 10, 2026, 02:39 PM UTC
L
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B
ANI Pharmaceuticals (NASDAQ: ANIP ) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140 bill
EARNINGS | Aug 07, 2026, 10:53 AM UTC
L
ANIP Initiated Hold and $91 PT @ Canaccord
ANIP Initiated Hold and $91 PT @ Canaccord
EQUITY | Jul 17, 2026, 12:29 PM UTC
L
ANIP Ani Pharmaceuticals announces intent to appeal rulings in Cg Oncology matter Ani Pharmaceuticals - trial court denies Ani Pharmaceutica
ANIP Ani Pharmaceuticals announces intent to appeal rulings in Cg Oncology matter Ani Pharmaceuticals - trial court denies Ani Pharmaceuticals' Motion for new trial and judgment Ani Pharmaceuticals Inc: continue to seek
EQUITY | Jul 16, 2026, 08:35 PM UTC